0001589150 true 09/30 2021 Q3 0001589150
2020-10-01 2021-06-30 0001589150 2021-06-30 0001589150 2020-09-30
0001589150 us-gaap:SeriesAPreferredStockMember 2021-06-30
0001589150 us-gaap:SeriesAPreferredStockMember 2020-09-30
0001589150 RGBP:SeriesAAPreferredStockMember 2021-06-30 0001589150
RGBP:SeriesAAPreferredStockMember 2020-09-30 0001589150
RGBP:SeriesMMember 2021-06-30 0001589150 RGBP:SeriesMMember
2020-09-30 0001589150 RGBP:SeriesNCMember 2021-06-30 0001589150
RGBP:SeriesNCMember 2020-09-30 0001589150 2021-04-01 2021-06-30
0001589150 2020-04-01 2020-06-30 0001589150 2019-10-01 2020-06-30
0001589150 RGBP:PreferredStockSeriesAMember 2019-09-30 0001589150
RGBP:SeriesAAPreferredStockMember 2019-09-30 0001589150
RGBP:SeriesNCPreferredStockMember 2019-09-30 0001589150
us-gaap:CommonStockMember 2019-09-30 0001589150
RGBP:SeriesMPreferredStockMember 2019-09-30 0001589150
us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001589150
us-gaap:RetainedEarningsMember 2019-09-30 0001589150
RGBP:ContributedCapitalMember 2019-09-30 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30
0001589150 us-gaap:NoncontrollingInterestMember 2019-09-30
0001589150 2019-09-30 0001589150 RGBP:PreferredStockSeriesAMember
2019-10-01 2019-12-31 0001589150 RGBP:SeriesAAPreferredStockMember
2019-10-01 2019-12-31 0001589150 RGBP:SeriesNCPreferredStockMember
2019-10-01 2019-12-31 0001589150 us-gaap:CommonStockMember
2019-10-01 2019-12-31 0001589150 RGBP:SeriesMPreferredStockMember
2019-10-01 2019-12-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31
0001589150 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31
0001589150 RGBP:ContributedCapitalMember 2019-10-01 2019-12-31
0001589150 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-10-01 2019-12-31 0001589150
us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31
0001589150 2019-10-01 2019-12-31 0001589150
RGBP:PreferredStockSeriesAMember 2019-12-31 0001589150
RGBP:SeriesAAPreferredStockMember 2019-12-31 0001589150
RGBP:SeriesNCPreferredStockMember 2019-12-31 0001589150
us-gaap:CommonStockMember 2019-12-31 0001589150
RGBP:SeriesMPreferredStockMember 2019-12-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001589150
us-gaap:RetainedEarningsMember 2019-12-31 0001589150
RGBP:ContributedCapitalMember 2019-12-31 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31
0001589150 us-gaap:NoncontrollingInterestMember 2019-12-31
0001589150 2019-12-31 0001589150 RGBP:PreferredStockSeriesAMember
2020-01-01 2020-03-31 0001589150 RGBP:SeriesAAPreferredStockMember
2020-01-01 2020-03-31 0001589150 RGBP:SeriesNCPreferredStockMember
2020-01-01 2020-03-31 0001589150 us-gaap:CommonStockMember
2020-01-01 2020-03-31 0001589150 RGBP:SeriesMPreferredStockMember
2020-01-01 2020-03-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31
0001589150 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31
0001589150 RGBP:ContributedCapitalMember 2020-01-01 2020-03-31
0001589150 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-01-01 2020-03-31 0001589150
us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31
0001589150 2020-01-01 2020-03-31 0001589150
RGBP:PreferredStockSeriesAMember 2020-03-31 0001589150
RGBP:SeriesAAPreferredStockMember 2020-03-31 0001589150
RGBP:SeriesNCPreferredStockMember 2020-03-31 0001589150
us-gaap:CommonStockMember 2020-03-31 0001589150
RGBP:SeriesMPreferredStockMember 2020-03-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001589150
us-gaap:RetainedEarningsMember 2020-03-31 0001589150
RGBP:ContributedCapitalMember 2020-03-31 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31
0001589150 us-gaap:NoncontrollingInterestMember 2020-03-31
0001589150 2020-03-31 0001589150 RGBP:PreferredStockSeriesAMember
2020-04-01 2020-06-30 0001589150 RGBP:SeriesAAPreferredStockMember
2020-04-01 2020-06-30 0001589150 RGBP:SeriesNCPreferredStockMember
2020-04-01 2020-06-30 0001589150 us-gaap:CommonStockMember
2020-04-01 2020-06-30 0001589150 RGBP:SeriesMPreferredStockMember
2020-04-01 2020-06-30 0001589150
us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30
0001589150 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30
0001589150 RGBP:ContributedCapitalMember 2020-04-01 2020-06-30
0001589150 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-04-01 2020-06-30 0001589150
us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30
0001589150 RGBP:PreferredStockSeriesAMember 2020-06-30 0001589150
RGBP:SeriesAAPreferredStockMember 2020-06-30 0001589150
RGBP:SeriesNCPreferredStockMember 2020-06-30 0001589150
us-gaap:CommonStockMember 2020-06-30 0001589150
RGBP:SeriesMPreferredStockMember 2020-06-30 0001589150
us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001589150
us-gaap:RetainedEarningsMember 2020-06-30 0001589150
RGBP:ContributedCapitalMember 2020-06-30 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30
0001589150 us-gaap:NoncontrollingInterestMember 2020-06-30
0001589150 2020-06-30 0001589150 RGBP:PreferredStockSeriesAMember
2020-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2020-09-30
0001589150 RGBP:SeriesNCPreferredStockMember 2020-09-30 0001589150
us-gaap:CommonStockMember 2020-09-30 0001589150
RGBP:SeriesMPreferredStockMember 2020-09-30 0001589150
us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001589150
us-gaap:RetainedEarningsMember 2020-09-30 0001589150
RGBP:ContributedCapitalMember 2020-09-30 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30
0001589150 us-gaap:NoncontrollingInterestMember 2020-09-30
0001589150 RGBP:PreferredStockSeriesAMember 2020-10-01 2020-12-31
0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2020-12-31
0001589150 RGBP:SeriesNCPreferredStockMember 2020-10-01 2020-12-31
0001589150 us-gaap:CommonStockMember 2020-10-01 2020-12-31
0001589150 RGBP:SeriesMPreferredStockMember 2020-10-01 2020-12-31
0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-10-01
2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-10-01
2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-10-01
2020-12-31 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01
2020-12-31 0001589150 us-gaap:NoncontrollingInterestMember
2020-10-01 2020-12-31 0001589150 2020-10-01 2020-12-31 0001589150
RGBP:PreferredStockSeriesAMember 2020-12-31 0001589150
RGBP:SeriesAAPreferredStockMember 2020-12-31 0001589150
RGBP:SeriesNCPreferredStockMember 2020-12-31 0001589150
us-gaap:CommonStockMember 2020-12-31 0001589150
RGBP:SeriesMPreferredStockMember 2020-12-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001589150
us-gaap:RetainedEarningsMember 2020-12-31 0001589150
RGBP:ContributedCapitalMember 2020-12-31 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31
0001589150 us-gaap:NoncontrollingInterestMember 2020-12-31
0001589150 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember
2021-01-01 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember
2021-01-01 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember
2021-01-01 2021-03-31 0001589150 us-gaap:CommonStockMember
2021-01-01 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember
2021-01-01 2021-03-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31
0001589150 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31
0001589150 RGBP:ContributedCapitalMember 2021-01-01 2021-03-31
0001589150 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-01-01 2021-03-31 0001589150
us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31
0001589150 2021-01-01 2021-03-31 0001589150
RGBP:PreferredStockSeriesAMember 2021-03-31 0001589150
RGBP:SeriesAAPreferredStockMember 2021-03-31 0001589150
RGBP:SeriesNCPreferredStockMember 2021-03-31 0001589150
us-gaap:CommonStockMember 2021-03-31 0001589150
RGBP:SeriesMPreferredStockMember 2021-03-31 0001589150
us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001589150
us-gaap:RetainedEarningsMember 2021-03-31 0001589150
RGBP:ContributedCapitalMember 2021-03-31 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31
0001589150 us-gaap:NoncontrollingInterestMember 2021-03-31
0001589150 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember
2021-04-01 2021-06-30 0001589150 RGBP:SeriesAAPreferredStockMember
2021-04-01 2021-06-30 0001589150 RGBP:SeriesNCPreferredStockMember
2021-04-01 2021-06-30 0001589150 us-gaap:CommonStockMember
2021-04-01 2021-06-30 0001589150 RGBP:SeriesMPreferredStockMember
2021-04-01 2021-06-30 0001589150
us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30
0001589150 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30
0001589150 RGBP:ContributedCapitalMember 2021-04-01 2021-06-30
0001589150 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-04-01 2021-06-30 0001589150
us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30
0001589150 RGBP:PreferredStockSeriesAMember 2021-06-30 0001589150
RGBP:SeriesAAPreferredStockMember 2021-06-30 0001589150
RGBP:SeriesNCPreferredStockMember 2021-06-30 0001589150
us-gaap:CommonStockMember 2021-06-30 0001589150
RGBP:SeriesMPreferredStockMember 2021-06-30 0001589150
us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001589150
us-gaap:RetainedEarningsMember 2021-06-30 0001589150
RGBP:ContributedCapitalMember 2021-06-30 0001589150
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30
0001589150 us-gaap:NoncontrollingInterestMember 2021-06-30
0001589150 srt:MinimumMember 2020-10-01 2021-06-30 0001589150
srt:MaximumMember 2020-10-01 2021-06-30 0001589150
RGBP:ZanderTherapeuticsMember 2021-06-30 0001589150
RGBP:DavidKoosMember 2021-06-30 0001589150 RGBP:BSTPartnersMember
2021-06-30 0001589150 RGBP:DavidKoosMember 2021-06-30 0001589150
RGBP:DavidKoosMember 2019-10-01 2020-09-30 0001589150
RGBP:BSTPartnersMember 2019-10-02 0001589150 RGBP:BSTPartnersMember
2019-10-01 2019-10-02 0001589150 RGBP:BSTPartnersMember 2019-10-04
0001589150 RGBP:BSTPartnersMember 2019-10-01 2019-10-04 0001589150
RGBP:BSTPartnersMember 2019-10-24 0001589150 RGBP:BSTPartnersMember
2019-10-01 2019-10-24 0001589150 RGBP:March82016Member 2021-06-30
0001589150 RGBP:March82016Member 2020-10-01 2021-06-30 0001589150
RGBP:April62016Member 2021-06-30 0001589150 RGBP:April62016Member
2020-10-01 2021-06-30 0001589150 RGBP:September82016Member
2020-10-01 2021-06-30 0001589150 RGBP:September82016Member
2021-06-30 0001589150 RGBP:September202016Member 2021-06-30
0001589150 RGBP:September202016Member 2020-10-01 2021-06-30
0001589150 RGBP:October312016Member 2021-06-30 0001589150
RGBP:October312016Member 2020-10-01 2021-06-30 0001589150
RGBP:October3120162Member 2021-06-30 0001589150
RGBP:October3120162Member 2020-10-01 2021-06-30 0001589150
RGBP:October3120163Member 2021-06-30 0001589150
RGBP:October3120163Member 2020-10-01 2021-06-30 0001589150
RGBP:December222016Member 2021-06-30 0001589150
RGBP:December222016Member 2020-10-01 2021-06-30 0001589150
RGBP:March12017Member 2021-06-30 0001589150 RGBP:March12017Member
2020-10-01 2021-06-30 0001589150 RGBP:March92017Member 2021-06-30
0001589150 RGBP:March92017Member 2020-10-01 2021-06-30 0001589150
RGBP:March132017Member 2021-06-30 0001589150 RGBP:March132017Member
2020-10-01 2021-06-30 0001589150 RGBP:March312017Member 2021-06-30
0001589150 RGBP:March312017Member 2020-10-01 2021-06-30 0001589150
RGBP:April192017Member 2021-06-30 0001589150 RGBP:April192017Member
2020-10-01 2021-06-30 0001589150 RGBP:April1920172Member 2021-06-30
0001589150 RGBP:April1920172Member 2020-10-01 2021-06-30 0001589150
RGBP:May52017Member 2021-06-30 0001589150 RGBP:May52017Member
2020-10-01 2021-06-30 0001589150 RGBP:May102017Member 2021-06-30
0001589150 RGBP:May102017Member 2020-10-01 2021-06-30 0001589150
RGBP:May192017Member 2021-06-30 0001589150 RGBP:May192017Member
2020-10-01 2021-06-30 0001589150 RGBP:June262017Member 2021-06-30
0001589150 RGBP:June262017Member 2020-10-01 2021-06-30 0001589150
RGBP:July242017Member 2021-06-30 0001589150 RGBP:July242017Member
2020-10-01 2021-06-30 0001589150 RGBP:Aug292017Member 2021-06-30
0001589150 RGBP:Aug292017Member 2020-10-01 2021-06-30 0001589150
RGBP:Sept222017Member 2021-06-30 0001589150 RGBP:Sept222017Member
2020-10-01 2021-06-30 0001589150 RGBP:Sept2220172Member 2021-06-30
0001589150 RGBP:Sept2220172Member 2020-10-01 2021-06-30 0001589150
RGBP:Sept252017Member 2021-06-30 0001589150 RGBP:Sept252017Member
2020-10-01 2021-06-30 0001589150 RGBP:Oct0317Member 2021-06-30
0001589150 RGBP:Oct0317Member 2020-10-01 2021-06-30 0001589150
RGBP:Oct0417Member 2021-06-30 0001589150 RGBP:Oct0417Member
2020-10-01 2021-06-30 0001589150 RGBP:Oct1617Member 2021-06-30
0001589150 RGBP:Oct1617Member 2020-10-01 2021-06-30 0001589150
RGBP:Nov0117Member 2021-06-30 0001589150 RGBP:Nov0117Member
2020-10-01 2021-06-30 0001589150 RGBP:Nov0120172Member 2021-06-30
0001589150 RGBP:Dec1517Member 2021-06-30 0001589150
RGBP:Dec1517Member 2020-10-01 2021-06-30 0001589150
RGBP:Dec2017Member 2021-06-30 0001589150 RGBP:Dec2017Member
2020-10-01 2021-06-30 0001589150 RGBP:Dec20172Member 2021-06-30
0001589150 RGBP:Dec20172Member 2020-10-01 2021-06-30 0001589150
RGBP:Dec0617Member 2021-06-30 0001589150 RGBP:Dec0617Member
2020-10-01 2021-06-30 0001589150 RGBP:Jan2418Member 2021-06-30
0001589150 RGBP:Jan2418Member 2020-10-01 2021-06-30 0001589150
RGBP:Feb2818Member 2021-06-30 0001589150 RGBP:Feb2818Member
2020-10-01 2021-06-30 0001589150 RGBP:May182018Member 2021-06-30
0001589150 RGBP:May182018Member 2020-10-01 2021-06-30 0001589150
RGBP:July112018Member 2021-06-30 0001589150
RGBP:September302018Member 2021-06-30 0001589150
RGBP:October32018Member 2021-06-30 0001589150
RGBP:October32018Member 2020-10-01 2021-06-30 0001589150
RGBP:February152019Member 2021-06-30 0001589150
RGBP:July192019Member 2021-06-30 0001589150 RGBP:July1920192Member
2021-06-30 0001589150 RGBP:July1920193Member 2021-06-30 0001589150
RGBP:July112018Member 2020-10-01 2021-06-30 0001589150
RGBP:July112018Member 2021-03-31 0001589150
RGBP:September302018Member 2021-03-31 0001589150
RGBP:DavidKoosMember 2021-03-31 0001589150 RGBP:BSTPartnersMember
2021-03-31 0001589150 RGBP:BSTPartnersMember 2021-04-01 2021-06-30
0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2021-06-30
0001589150 us-gaap:SeriesAMember 2020-10-01 2021-06-30 0001589150
RGBP:SeriesMMember 2020-10-01 2021-06-30 0001589150
RGBP:SeriesMPreferredStockMember 2021-06-30 0001589150
RGBP:ZanderTherapeuticsMember 2018-05-30 2018-06-11 0001589150
RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2018-11-01
2018-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2020-10-01
2021-06-30 0001589150 RGBP:SeriesMMember
RGBP:ZanderTherapeuticsMember 2020-10-01 2021-06-30 0001589150
RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-06-30
0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember
2021-06-30 0001589150 us-gaap:CommonStockMember
RGBP:ZanderTherapeuticsMember 2020-10-01 2021-06-30 0001589150
RGBP:UnrelatedPartyMember 2020-10-01 2021-06-30 0001589150
RGBP:ZanderTherapeuticsMember 2020-10-01 2021-06-30 0001589150
us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2021-06-30
0001589150 RGBP:SeriesMMember RGBP:OncologyPharmaMember 2020-10-01
2021-06-30 0001589150 us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember 2021-04-01 2021-04-12 0001589150
us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-04-01
2021-04-13 0001589150 us-gaap:ConvertibleDebtMember
RGBP:SeriesNCPreferredStockMember srt:ChiefExecutiveOfficerMember
2021-04-01 2021-04-13 0001589150 us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember 2021-04-02 2021-04-13 0001589150
us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-04-01
2021-04-15 0001589150 us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember 2021-04-02 2021-04-15 0001589150
us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-04-01
2021-04-16 0001589150 us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember 2021-04-02 2021-04-16 0001589150
us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-04-01
2021-04-21 0001589150 us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember 2021-04-01 2021-04-28 0001589150
us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-05-01
2021-05-03 0001589150 us-gaap:ConvertibleDebtMember
us-gaap:CommonStockMember 2021-05-01 2021-05-05 0001589150
us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2021-05-01
2021-05-18 0001589150 RGBP:AsOriginallyPresentedMember 2021-04-01
2021-06-30 0001589150 srt:RestatementAdjustmentMember 2021-04-01
2021-06-30 0001589150 RGBP:AsRestatedMember 2021-04-01 2021-06-30
0001589150 RGBP:AsOriginallyPresentedMember 2020-10-01 2021-06-30
0001589150 srt:RestatementAdjustmentMember 2020-10-01 2021-06-30
0001589150 RGBP:AsRestatedMember 2020-10-01 2021-06-30 0001589150
RGBP:AsOriginallyPresentedMember 2021-06-30 0001589150
srt:RestatementAdjustmentMember 2021-06-30 0001589150
RGBP:AsRestatedMember 2021-06-30 iso4217:USD xbrli:shares
iso4217:USD xbrli:shares xbrli:pure
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
10-Q/A
Amendment
1
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended
June 30, 2021
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For
the transition period from
Commission File
No.
333-191725
REGEN BIOPHARMA,
INC.
(Exact name
of small business issuer as specified in its
charter)
Nevada |
45-5192997 |
(State or
other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
4700 Spring Street,
St 304, La Mesa, California
91942
(Address of
Principal Executive Offices)
619 722-5505
(Issuer’s
telephone number)
None
(Former
name, address and fiscal year, if changed since last
report)
Check
whether the issuer (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the preceding 12
months (or for such shorter period that the issuer was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes ☐
No ☒
Indicate by
check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required
to submit and post such files).
Yes ☐
No ☒
Indicate by
check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,”
“accelerated filer,” “non-accelerated filer,” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
☐ Large
accelerated filer |
☐ Accelerated
filer |
☐ Non-accelerated
filer |
☒ Smaller reporting company |
☐
APPLICABLE
ONLY TO CORPORATE ISSUERS:
As of June
30, 2021 Regen Biopharma, Inc. had 3,780,195,788
common shares outstanding.
As of June
30, 2021 Regen Biopharma, Inc. had 414, 147,858 shares of Series A
Preferred Stock outstanding.
As of June
30, 2021 Regen Biopharma, Inc. had 50,000 shares of Series AA
Preferred Stock outstanding.
As of June
30,2021 Regen Biopharma, Inc. had 44,000,000 shares of Series M
Preferred Stock outstanding.
As of June
30,2021 Regen Biopharma, Inc. had 10,000 shares of Series NC
Preferred Stock outstanding
Indicate by
check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act): Yes ☐
No ☒
EXPLANATORY NOTE:
THIS AMENDMENT NO.1 TO REGEN BIOPHARMA INC’S (THE “COMPANY”) FORM
10-Q FOR THE PERIOD ENDED JUNE 30, 2021 (“(“ORIGINAL FILING”) IS
BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF THE ORIGINAL
FILING.
PART 1,
ITEM 1 FINANCIAL STATEMENTS
PART 1,
ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS.
PART II,
ITEM 1 LEGAL PROCEEDINGS
THE
COMPANY HAS NOT MODIFIED OR UPDATED DISCLOSURES PRESENTED IN THE
ORIGINAL FILING, EXCEPT AS INDICATED ABOVE. ACCORDINGLY, THIS
AMENDMENT DOES NOT REFLECT EVENTS OCCURRING AFTER THE DATE OF THE
ORIGINAL FILING AND DOES NOT MODIFY OR UPDATE THOSE DISCLOSURES
AFFECTED BY SUBSEQUENT EVENTS, EXCEPT AS SPECIFICALLY REFERENCED
HEREIN. INFORMATION NOT AFFECTED BY THE ABOVE AMENDMENTS IS
UNCHANGED AND REFLECTS THE DISCLOSURES MADE AT THE TIME OF THE
ORIGINAL FILING.
PART I -
FINANCIAL INFORMATION
Item 1. -
Financial Statements
Report of Independent Registered
Public Accounting Firm
To the shareholders and the board of
directors of Regen Biopharma, Inc.
Opinion on the Financial
Statements
We have audited the accompanying
consolidated balance sheets of Regen Biopharma, Inc. as of
September 30, 2021 and 2020, the related statements of operations,
stockholders' equity (deficit), and cash flows for the years then
ended, and the related notes (collectively referred to as the
"financial statements"). In our opinion, the financial statements
present fairly, in all material respects, the financial position of
the Company as of September 30, 2021 and 2020, and the results of
its operations and its cash flows for the years then ended, in
conformity with accounting principles generally accepted in the
United States.
Substantial Doubt about the
Company’s Ability to Continue as a Going Concern
The accompanying financial statements
have been prepared assuming that the Company will continue as a
going concern. As discussed in Note 3 to the financial statements,
the Company has suffered recurring losses from operations and has a
significant accumulated deficit. In addition, the Company continues
to experience negative cash flows from operations. These factors
raise substantial doubt about the Company's ability to continue as
a going concern. Management's plans in regard to these matters are
also described in Note 3. The financial statements do not include
any adjustments that might result from the outcome of this
uncertainty.
Basis for Opinion
These financial statements are the
responsibility of the Company's management. Our responsibility is
to express an opinion on the Company's financial statements based
on our audit. We are a public accounting firm registered with the
Public Company Accounting Oversight Board (United States) ("PCAOB")
and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and
the PCAOB.
We conducted our audit in accordance
with the standards of the PCAOB. Those standards require that we
plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement,
whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audits we are required to
obtain an understanding of internal control over financial
reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion.
Our audit included performing
procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a
reasonable basis for our opinion.
/S/ BF Borgers CPA PC
BF Borgers CPA PC
We have served as the Company's
auditor since 2021
Lakewood, CO
December 22, 2021
REGEN BIOPHARMA ,
INC. |
|
|
|
|
CONSOLIDATED BALANCE
SHEETS |
|
|
|
|
|
|
|
|
|
|
|
As of
June 30, 2021
(unaudited)
(as restated) |
|
As of
September 30, 2020 |
ASSETS |
|
|
|
|
CURRENT
ASSETS |
|
|
|
|
|
|
|
|
Cash |
|
$ |
188,179 |
|
|
$ |
— |
|
Accounts
Receivable, Related Party |
|
|
185,466 |
|
|
|
103,192 |
|
Note
Receivable, Related Party |
|
|
5,396 |
|
|
|
0 |
|
Accrued
Interest Receivable |
|
|
96 |
|
|
|
0 |
|
Prepaid
Expenses |
|
|
0 |
|
|
|
28 |
|
|
|
|
|
|
|
|
|
|
Total
Current Assets |
|
|
379,137 |
|
|
|
103,220 |
|
|
|
|
|
|
|
|
|
|
OTHER
ASSETS |
|
|
|
|
|
|
|
|
Investment
Securities |
|
|
1,034,550 |
|
|
|
0 |
|
Investment
Securities, Related Party |
|
|
19,969 |
|
|
|
19,969 |
|
Total Other
Assets |
|
|
1,054,519 |
|
|
|
19,969 |
|
|
|
|
|
|
|
|
|
|
TOTAL
ASSETS |
|
$ |
1,433,656 |
|
|
$ |
123,189 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current
Liabilities: |
|
|
|
|
|
|
|
|
Accounts
payable |
|
|
100,223 |
|
|
|
110,486 |
|
Notes
Payable |
|
|
14,227 |
|
|
|
62,127 |
|
Accrued
payroll taxes |
|
|
4,241 |
|
|
|
4,241 |
|
Accrued
Interest |
|
|
960,453 |
|
|
|
830,061 |
|
Accrued
Rent |
|
|
23,548 |
|
|
|
23,548 |
|
Accrued
Payroll |
|
|
1,266,679 |
|
|
|
1,189,319 |
|
Other
Accrued Expenses |
|
|
41,423 |
|
|
|
41,423 |
|
Bank
Overdraft |
|
|
1,000 |
|
|
|
1,000 |
|
Due to
Investor |
|
|
20,000 |
|
|
|
20,000 |
|
Unearned
Income |
|
|
1,875,794 |
|
|
|
|
|
Derivative
Liability |
|
|
7,173,677 |
|
|
|
2,634,215 |
|
Convertible
Notes Payable Less unamortized discount |
|
|
2,342,575 |
|
|
|
2,522,716 |
|
Convertible
Notes Payable, Related Parties Less unamortized
discount |
|
|
21,500 |
|
|
|
19,050 |
|
Total
Current Liabilities |
|
|
13,845,341 |
|
|
|
7,458,187 |
|
Long Term
Liabilities: |
|
|
|
|
|
|
|
|
Convertible
Notes Payable, Related Parties Less unamortized
discount |
|
|
|
|
|
|
0 |
|
Total Long
Term Liabilities |
|
|
|
|
|
|
|
|
Total
Liabilities |
|
|
13,845,341 |
|
|
|
7,458,187 |
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS' EQUITY
(DEFICIT) |
|
|
|
|
|
|
|
|
Common Stock
($.0001 par value)
500,000,000 shares authorized; 4,800,000,000
authorized and 1,605,000,246
issued and outstanding as of September 30, 2020 and 4,800,000,000
authorized and 3,780,195,788
shares issued and outstanding June 30,2021. |
|
|
378,018 |
|
|
|
160,498 |
|
Preferred
Stock, 0.0001 par value,
800,000,000
authorized as of June 30,2021 and September 30,2020
respectively |
|
|
|
|
|
|
|
|
Series A
Preferred 300,000,000
authorized, 381,768,689 and
414,147,858
outstanding as of September 30,2020 and June 30, 2021
respectively |
|
|
41,415 |
|
|
|
38,177 |
|
Series AA
Preferred $0.0001 par value
600,000
authorized and 50,000 and
50,000
outstanding as of June 30,2021 and September 30,2020
respectively |
|
|
5 |
|
|
|
5 |
|
Series M
Preferred $0.0001 par value
300,000,000
authorized and 44,000,000
outstanding as of June 30,2021 and September 30, 2020
respectively |
|
|
4,400 |
|
|
|
4,400 |
|
Series NC
Preferred $0.0001 par value
20,000 and
0 authorized and
10,000 and
0 outstanding
as of June 30, 2021 and September 30,2020 respectively |
|
|
1 |
|
|
|
0 |
|
Additional
Paid in capital |
|
|
8,392,382 |
|
|
|
8,313,877 |
|
Contributed
Capital |
|
|
736,326 |
|
|
|
731,711 |
|
Retained
Earnings (Deficit) |
|
|
(21,964,232 |
) |
|
|
(16,583,666 |
) |
|
|
|
|
|
|
|
|
|
Total
Stockholders' Equity (Deficit) |
|
|
(12,411,685 |
) |
|
|
(7,334,998 |
) |
|
|
|
|
|
|
|
|
|
TOTAL
LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) |
|
$ |
1,433,656 |
|
|
$ |
123,189 |
|
|
|
|
|
|
|
|
|
|
The
Accompanying Notes are an Integral Part of These Financial
Statements |
REGEN
BIOPHARMA , INC.
Condensed
Consolidated Statement of Shareholder's Deficit
(unaudited)
Nine
Months Ended June 2020 and 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series
A Preferred |
|
Series AA
Preferred |
|
Series NC
Preferred |
|
Common |
|
Series M
Preferred |
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Additional
Paid-in Capital |
|
Retained
Earnings |
|
Contributed
Capital |
|
Accumulated
Other Comprehensive Income (Loss) |
|
Noncontrolling
Interest |
|
Total |
Balance
September 30, 2019 |
|
Balance
September 30, 2019 |
|
|
348,376,230 |
|
|
$ |
34,838 |
|
|
|
50,000 |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
600,001,406 |
|
|
$ |
59,998 |
|
|
|
38,000,000 |
|
|
$ |
3,800 |
|
|
$ |
8,261,993 |
|
|
$ |
(19,998,086 |
) |
|
$ |
728,658 |
|
|
$ |
— |
|
|
$- |
|
$(10,908,795) |
Shares
issued for Debt |
10/29/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,100,608 |
|
|
|
1,510 |
|
|
|
|
|
|
|
|
|
|
|
3,397 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,907 |
Shares
issued for Interest |
10/29/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,376,007 |
|
|
|
438 |
|
|
|
|
|
|
|
|
|
|
|
984 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,422 |
Shares
issued for debt |
10/29/2019 |
Shares
issued for debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,834,497 |
|
|
|
2,083 |
|
|
|
|
|
|
|
|
|
|
|
7,917 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000 |
Shares
Issued for Interest |
10/29/2019 |
Shares
Issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,418,941 |
|
|
|
342 |
|
|
|
|
|
|
|
|
|
|
|
1,299 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,641 |
Shares
issued for Debt |
11/5/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25,002,163 |
|
|
|
2,500 |
|
|
|
|
|
|
|
|
|
|
|
6,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,000 |
Shares
Issued for Interest |
11/5/2019 |
Shares
Issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,217,031 |
|
|
|
422 |
|
|
|
|
|
|
|
|
|
|
|
1,096 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,518 |
Shares
issued for Debt |
11/5/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,254,584 |
|
|
|
1,925 |
|
|
|
|
|
|
|
|
|
|
|
3,850 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,775 |
Shares
Issued for Interest |
11/5/2019 |
Shares
Issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,745,416 |
|
|
|
875 |
|
|
|
|
|
|
|
|
|
|
|
1,750 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,625 |
Shares
issued for Debt |
11/5/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,555,555 |
|
|
|
3,056 |
|
|
|
|
|
|
|
|
|
|
|
7,944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,000 |
Shares
issued for Services |
11/15/2019 |
Shares
issued for Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,000,000 |
|
|
|
600 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600 |
Shares
issued for Interest |
11/27/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,946,444 |
|
|
|
3,095 |
|
|
|
|
|
|
|
|
|
|
|
(310 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,785 |
Shares
issued for Fees |
11/27/2019 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,555,556 |
|
|
|
556 |
|
|
|
|
|
|
|
|
|
|
|
(56 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500 |
Shares
issued for Debt |
11/27/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,500,000 |
|
|
|
3,650 |
|
|
|
|
|
|
|
|
|
|
|
2,920 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,570 |
Shares
Issued for Debt |
11/27/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,251,177 |
|
|
|
3,125 |
|
|
|
|
|
|
|
|
|
|
|
3,625 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,750 |
Shares
issued for Interest |
11/27/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,393,684 |
|
|
|
439 |
|
|
|
|
|
|
|
|
|
|
|
510 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
Shares
Issued for Debt |
12/3/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,558,094 |
|
|
|
3,056 |
|
|
|
|
|
|
|
|
|
|
|
2,444 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,500 |
Shares
issued for Interest |
12/3/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,556,017 |
|
|
|
556 |
|
|
|
|
|
|
|
|
|
|
|
444 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,000 |
Shares
Issued for Debt |
12/4/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,234,276 |
|
|
|
3,123 |
|
|
|
|
|
|
|
|
|
|
|
2,967 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,090 |
Shares
issued for Interest |
12/4/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,308,288 |
|
|
|
531 |
|
|
|
|
|
|
|
|
|
|
|
504 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,035 |
Shares
Issued for Debt |
12/5/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41,922,222 |
|
|
|
4,192 |
|
|
|
|
|
|
|
|
|
|
|
3,354 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,546 |
Shares
Issued for Debt |
12/6/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,064,761 |
|
|
|
1,006 |
|
|
|
|
|
|
|
|
|
|
|
(99 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
907 |
Shares
issued for Interest |
12/6/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,310,416 |
|
|
|
2,631 |
|
|
|
|
|
|
|
|
|
|
|
(260 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,371 |
Shares
issued for Fees |
12/6/2019 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,548,380 |
|
|
|
555 |
|
|
|
|
|
|
|
|
|
|
|
(55 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500 |
Shares
Issued for Debt |
12/10/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49,729,272 |
|
|
|
4,973 |
|
|
|
|
|
|
|
|
|
|
|
905 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,878 |
Shares
Issued for Debt |
12/13/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,777,157 |
|
|
|
3,778 |
|
|
|
|
|
|
|
|
|
|
|
(1,512 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,266 |
Shares
issued for Interest |
12/13/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,101,694 |
|
|
|
610 |
|
|
|
|
|
|
|
|
|
|
|
(244 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
366 |
Shares
issued for Fees |
12/13/2019 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,335,648 |
|
|
|
834 |
|
|
|
|
|
|
|
|
|
|
|
(334 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500 |
Shares
Issued for Debt |
12/13/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52,200,000 |
|
|
|
5,220 |
|
|
|
|
|
|
|
|
|
|
|
(2,088 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,132 |
Shares
Issued for Debt |
12/16/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,081,411 |
|
|
|
4,208 |
|
|
|
|
|
|
|
|
|
|
|
1,262 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,470 |
Shares
issued for Interest |
12/16/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,677,742 |
|
|
|
768 |
|
|
|
|
|
|
|
|
|
|
|
230 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
Shares
Issued for Debt |
12/19/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41,433,258 |
|
|
|
4,143 |
|
|
|
|
|
|
|
|
|
|
|
3,314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,457 |
Shares
issued for Interest |
12/19/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
566,742 |
|
|
|
57 |
|
|
|
|
|
|
|
|
|
|
|
45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
102 |
Shares
Issued for Debt |
12/20/2019 |
Shares
Issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,462,834 |
|
|
|
5,046 |
|
|
|
|
|
|
|
|
|
|
|
(1,766 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,280 |
Shares
issued for Interest |
12/20/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,477,166 |
|
|
|
948 |
|
|
|
|
|
|
|
|
|
|
|
(332 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
616 |
Shares
issued for Debt |
12/20/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59,900,000 |
|
|
|
5,990 |
|
|
|
|
|
|
|
|
|
|
|
(2,396 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,594 |
Shares
issued for Debt |
12/23/2019 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,421,505 |
|
|
|
3,142 |
|
|
|
|
|
|
|
|
|
|
|
(2,200 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
942 |
Shares
issued for Interest |
12/23/2019 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,808,081 |
|
|
|
1,181 |
|
|
|
|
|
|
|
|
|
|
|
(827 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
Shares
issued for Fees |
12/23/2019 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,678,081 |
|
|
|
1,668 |
|
|
|
|
|
|
|
|
|
|
|
(1,168 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500 |
Capital
contribution quarter ended 12/31/2019 |
|
Capital
contribution quarter ended 12/31/2019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
|
|
|
|
|
|
|
|
133 |
Net
Income Quarter Ended 12/31/2019 |
|
Net Income
Quarter Ended 12/31/2019 |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
3,082,768 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
3,083,375 |
Balance
December 31, 2019 |
|
Balance
December 31, 2019 |
|
|
348,376,230 |
|
|
$ |
34,838 |
|
|
|
50,000 |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
1,422,306,114 |
|
|
$ |
142,228 |
|
|
|
44,000,000 |
|
|
$ |
4,400 |
|
|
$ |
8,305,609 |
|
|
$ |
(16,915,318 |
) |
|
$ |
728,791 |
|
|
|
— |
|
|
— |
|
$(7,699,447) |
Shares
issued for Debt |
1/2/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69,685,185 |
|
|
|
6,969 |
|
|
|
|
|
|
|
|
|
|
|
(3,206 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,763 |
Shares
issued for Debt |
1/2/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,826,333 |
|
|
|
3,683 |
|
|
|
|
|
|
|
|
|
|
|
(2,578 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,105 |
Shares
issued for Interest |
1/2/2020 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,480,000 |
|
|
|
1,748 |
|
|
|
|
|
|
|
|
|
|
|
(1,224 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
524 |
Shares
issued for Fees |
1/2/2020 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,666,667 |
|
|
|
1,667 |
|
|
|
|
|
|
|
|
|
|
|
(1,167 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500 |
Shares
issued for Debt |
1/23/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,739,096 |
|
|
|
674 |
|
|
|
|
|
|
|
|
|
|
|
(472 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
202 |
Shares
issued for Interest |
1/23/2020 |
Shares
issued for Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,615,919 |
|
|
|
1,862 |
|
|
|
|
|
|
|
|
|
|
|
(1,304 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
558 |
Shares
issued for Fees |
1/23/2020 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,680,931 |
|
|
|
1,668 |
|
|
|
|
|
|
|
|
|
|
|
(1,168 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500 |
Net Loss
Quarter Ended March 31,2020 |
|
Net Loss
Quarter Ended March 31,2020 |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
(4,077,145 |
) |
|
|
—
|
|
|
|
—
|
|
|
— |
|
(4,077,145) |
Balance
March 31, 2020 |
|
Balance
March 31, 2020 |
|
|
348,376,230 |
|
|
$ |
34,838 |
|
|
|
50,000 |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
1,605,000,246 |
|
|
$ |
160,498 |
|
|
|
44,000,000 |
|
|
$ |
4,400 |
|
|
$ |
8,294,491 |
|
|
$ |
(20,992,464 |
) |
|
$ |
728,791 |
|
|
|
—
|
|
|
—
|
|
$(11,769,440) |
Preferred
Shares issued for Debt |
5/12/2020 |
Preferred
Shares issued for Debt |
|
|
3550977 |
|
|
|
355 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,645 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000 |
Preferred
Shares issued for Interest |
5/12/2020 |
Preferred
Shares issued for Interest |
|
|
1687898 |
|
|
|
169 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,257 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,426 |
Net
Income ( Loss) Quarter Ended June 30, 2020 |
|
Net Income (
Loss) Quarter Ended June 30, 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
|
|
3,205,944 |
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
3,205,944 |
Balance
June 30, 2020 |
|
Balance June
30, 2020 |
|
|
353,615,105 |
|
|
$ |
35,362 |
|
|
|
50,000 |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
1,605,000,246 |
|
|
$ |
160,498 |
|
|
|
44,000,000 |
|
|
$ |
4,400 |
|
|
$ |
8,298,393 |
|
|
$ |
(17,786,519 |
) |
|
$ |
728,791 |
|
|
|
—
|
|
|
— |
|
$(8,559,070) |
Balance
September 30,2020 |
|
Balance
September 30,2020 |
|
|
381,768,689 |
|
|
$ |
38,177 |
|
|
|
50,000 |
|
|
|
5 |
|
|
|
— |
|
|
|
— |
|
|
|
1,605,000,246 |
|
|
$ |
160,498 |
|
|
|
44,000,000 |
|
|
$ |
4,400 |
|
|
$ |
8,313,876 |
|
|
$ |
(16,583,666 |
) |
|
$ |
731,711 |
|
|
|
— |
|
|
— |
|
$(7,334,998) |
Shares
issued for Debt |
10/28/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
57,726,183 |
|
|
|
5,773 |
|
|
|
|
|
|
|
|
|
|
|
(2,021 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,752 |
Shares
Issued For Interest |
10/28/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,339,663 |
|
|
|
2,234 |
|
|
|
|
|
|
|
|
|
|
|
(782 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,452 |
Shares
issued for Debt |
11/6/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,007,919 |
|
|
|
6,001 |
|
|
|
|
|
|
|
|
|
|
|
(2,101 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,900 |
Shares
Issued For Interest |
11/6/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,926,234 |
|
|
|
2,393 |
|
|
|
|
|
|
|
|
|
|
|
(838 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,555 |
Shares
issued for Debt |
12/11/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,834,498 |
|
|
|
6,083 |
|
|
|
|
|
|
|
|
|
|
|
1,217 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,300 |
Shares
Issued For Interest |
12/11/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,185,501 |
|
|
|
2,619 |
|
|
|
|
|
|
|
|
|
|
|
523 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,142 |
Shares
issued for Debt |
12/16/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,300,000 |
|
|
|
330 |
|
|
|
|
|
|
|
|
|
|
|
99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
429 |
Shares
Issued For Interest |
12/16/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,819,077 |
|
|
|
182 |
|
|
|
|
|
|
|
|
|
|
|
54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
236 |
Shares
issued for Fees |
12/16/2020 |
Shares
issued for Fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,228,077 |
|
|
|
123 |
|
|
|
|
|
|
|
|
|
|
|
36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
159 |
Shares
issued for Debt |
12/16/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,003,571 |
|
|
|
6,200 |
|
|
|
|
|
|
|
|
|
|
|
(2,170 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,030 |
Shares
Issued For Interest |
12/16/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26,155,352 |
|
|
|
2,616 |
|
|
|
|
|
|
|
|
|
|
|
(916 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,700 |
Shares
issued for Debt |
12/17/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
68,333,539 |
|
|
|
6,833 |
|
|
|
|
|
|
|
|
|
|
|
1,367 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,200 |
Shares
Issued For Interest |
12/17/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,883,378 |
|
|
|
1,488 |
|
|
|
|
|
|
|
|
|
|
|
212 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,700 |
Shares
issued for Debt |
12/17/2020 |
Shares
issued for Debt |
|
|
20,000,437 |
|
|
|
2,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,000 |
Shares
Issued For Interest |
12/17/2020 |
Shares
Issued For Interest |
|
|
12,378,732 |
|
|
|
1,238 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,808 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,046 |
Shares
issued for Debt |
12/23/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
88,888,889 |
|
|
|
8,889 |
|
|
|
|
|
|
|
|
|
|
|
7,111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,000 |
Shares
Issued For Interest |
12/23/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19,555,555 |
|
|
|
1,956 |
|
|
|
|
|
|
|
|
|
|
|
1,294 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,250 |
Shares
issued for Debt |
12/31/2020 |
Shares
issued for Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
82,004,603 |
|
|
|
8,200 |
|
|
|
|
|
|
|
|
|
|
|
(2,870 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,330 |
Shares
Issued For Interest |
12/31/2020 |
Shares
Issued For Interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,832,781 |
|
|
|
3,583 |
|
|
|
|
|
|
|
|
|
|
|
(1,254 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,329 |
Additions
to Contributed Capital Quarter ended 12/31/2020 |
|
Additions to
Contributed Capital Quarter ended 12/31/2020 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,865 |
|
|
|
|
|
|
|
|
1,865 |
Net Loss
Quarter Ended December 31,2020 |
|
Net Loss
Quarter Ended December 31,2020 |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
1,666,367 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
1,666,367 |
Balance
December 31, 2020 |
|
Balance
December 31, 2020 |
|
|
414,147,858 |
|
|
$ |
41,415 |
|
|
|
50,000 |
|
|
|
5 |
|
|
|
— |
|
|
|
|
|
|
|
2,260,025,066 |
|
|
$ |
226,001 |
|
|
|
44,000,000 |
|
|
$ |
4,400 |
|
|
$ |
8,330,646 |
|
|
$ |
(14,917,299 |
|